Onapristone ER: Phase I/II started

Arno began an open-label, U.K. Phase I/II trial to evaluate 10, 20, 30, 40 and 50 mg oral onapristone ER twice daily in about 60 patients with advanced CRPC after failure of Zytiga abiraterone or Xtandi enzalutamide. The trial will also use a companion diagnostic developed by Arno to select patients whose prostate cancer expresses the activated form of the progesterone receptor. Onapristone is also in Phase I testing for progesterone receptor-positive solid tumors. Arno has exclusive, worldwide rights to develop and commercialize onapristone from Invivis under a 2012 deal (see BioCentury, Feb. 20, 2012). ...